Patient characteristics in the 2 therapy groups
| Characteristic . | High-dose sequential therapy (n = 10) . | Rituximab + high-dose sequential therapy (n = 15) . |
|---|---|---|
| Sex (male/female) | 5/5 | 11/4 |
| Median age, y (range) | 46 (36-53) | 43 (34-58) |
| Histologic findings | ||
| Follicular disease (grade 1 or 2) | 6 | 6 |
| Follicular disease (grade 3) | 1 | 1 |
| Mantle cell disease | 3 | 7 |
| Mucosa-associated lymphoid tissue lymphoma | — | 1 |
| Molecular rearrangement | ||
| Bcl1 | 3 | 3 |
| Bcl2 | 6 | 4 |
| IgH | 1 | 8 |
| Stage | ||
| III | 1 | 4 |
| IV | 9 | 11 |
| B-cell lymphoma symptoms | 0 | 4 |
| Mass greater than 10 cm | 3 | 0 |
| Sites of involvement | ||
| Nodal sites (including spleen) | 10 | 14 |
| Extranodal sites (excluding BM) | 3 | 2 |
| BM involvement (histologic) | 7 | 11 |
| BM involvement (PCR only) | 3 | 4 |
| Lymphoma cells in PB (morphologic) | 3 | 6 |
| Characteristic . | High-dose sequential therapy (n = 10) . | Rituximab + high-dose sequential therapy (n = 15) . |
|---|---|---|
| Sex (male/female) | 5/5 | 11/4 |
| Median age, y (range) | 46 (36-53) | 43 (34-58) |
| Histologic findings | ||
| Follicular disease (grade 1 or 2) | 6 | 6 |
| Follicular disease (grade 3) | 1 | 1 |
| Mantle cell disease | 3 | 7 |
| Mucosa-associated lymphoid tissue lymphoma | — | 1 |
| Molecular rearrangement | ||
| Bcl1 | 3 | 3 |
| Bcl2 | 6 | 4 |
| IgH | 1 | 8 |
| Stage | ||
| III | 1 | 4 |
| IV | 9 | 11 |
| B-cell lymphoma symptoms | 0 | 4 |
| Mass greater than 10 cm | 3 | 0 |
| Sites of involvement | ||
| Nodal sites (including spleen) | 10 | 14 |
| Extranodal sites (excluding BM) | 3 | 2 |
| BM involvement (histologic) | 7 | 11 |
| BM involvement (PCR only) | 3 | 4 |
| Lymphoma cells in PB (morphologic) | 3 | 6 |
BM indicates bone marrow; PCR, polymerase chain reaction; and PB, peripheral blood.